Summary

Clinical outcomes, including mortality, are improved with the use of a dual angiotensin receptor blocker-neprilysin inhibitor (ARNI), LCZ696, compared with the existing gold standard in the treatment of patients with chronic heart failure (CHF). iscussed findings and insights from a study that evaluated the efficacy and safety of LCZ696 vs enalapril on the morbidity and mortality of patients with CHF-namely, the PARADIGM-HF trial.